Basic research progress in targeted immunotherapy for multiple system atrophy
10.3760/cma.j.cn113694-20250604-00331
- VernacularTitle:多系统萎缩靶向免疫治疗的基础研究进展
- Author:
Huanchang XU
1
;
Huijing LIU
1
;
Wen SU
1
Author Information
1. 北京医院神经内科 国家老年医学中心 中国医学科学院老年医学研究院 北京协和医学院，北京 100730
- Publication Type:Journal Article
- Keywords:
Multiple system atrophy;
alpha-Synuclein;
Immunotherapy;
Immunization, active;
Immunization, passive
- From:
Chinese Journal of Neurology
2025;58(11):1228-1234
- CountryChina
- Language:Chinese
-
Abstract:
Currently, the clinical management of multiple system atrophy (MSA) is primarily limited to symptomatic treatment. While existing medications can partially alleviate motor symptoms and autonomic dysfunction, their overall efficacy remains unsatisfactory, and there is a lack of effective disease-modifying therapies. In recent years, with the deepening understanding of disease mechanisms, alpha-synuclein, identified as a key pathogenic factor, has become a major target in MSA therapeutic research. This article concentrates on targeted immunotherapy and reviews recent global and domestic advances, aiming to provide a theoretical reference for the development of novel therapeutic strategies for MSA.
